Harvard Bioscience Reports Significant FY25 Net Loss Driven by Goodwill Impairment; Provides 2026 Guidance
HBIO sits 77% above its 52-week low of $0.281.
Summary
Harvard Bioscience reported a substantial net loss of $56.7 million for fiscal year 2025, primarily due to a $48.0 million goodwill impairment, alongside declining revenues, though adjusted EBITDA and cash flow improved, and the company provided modest growth guidance for 2026.
Key Events · Earnings and Guidance · HBIO
-
Significant FY25 Net Loss
The company reported a net loss of $56.7 million for fiscal year 2025, a substantial increase from a $12.4 million net loss in 2024.
-
Major Goodwill Impairment
The significant FY25 net loss was primarily driven by a $48.0 million goodwill impairment charge recorded in the first quarter of 2025.
-
Revenue Decline
Full-year 2025 revenues decreased to $86.6 million from $94.1 million in 2024, and fourth-quarter 2025 revenues also saw a slight decline to $23.7 million from $24.6 million year-over-year.
-
Improved Adjusted Metrics
Despite the net loss, adjusted EBITDA for FY25 increased to $8.1 million from $7.2 million, and cash provided by operations significantly improved to $6.7 million from $1.4 million in the prior year.
Analysis · HBIO · Industrial Applications And Services
Harvard Bioscience's latest 8-K reveals a challenging fiscal year 2025, marked by a significant net loss of $56.7 million, largely attributable to a $48.0 million goodwill impairment charge. This impairment, representing over double the company's current market capitalization, signals a substantial write-down of asset value and raises concerns about the company's underlying business health. While the company reported improved adjusted EBITDA and cash flow from operations, and projects modest revenue and EBITDA growth for 2026, the magnitude of the net loss and revenue decline for 2025 presents a significant negative signal. Investors should monitor the company's ability to execute on its new product innovation strategy for translational science and achieve its 2026 guidance to offset the substantial losses incurred in 2025.
At the time of this filing, HBIO was trading at $0.50 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $22.7M. The 52-week trading range was $0.28 to $0.95. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.